Partner Brent Babcock was quoted in “Why the University of California is Appealing the CRISPR Patent Decision,” an article published in The Atlantic.
Excerpt: So it continues. In February, the U.S. Patent and Trademark Office decided in favor of the Broad Institute of Harvard and the Massachusetts Institute of Technology, which has been battling for years with the University of California over patents for the gene-editing technology CRISPR-Cas9, often shorthanded as CRISPR. On Thursday, the University of California filed its an appeal, as many expected, with the United States Court of Appeals for the Federal Circuit.